Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBT (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed EBT for 12 consecutive years, with -$25.5 million as the latest value for Q1 2026.

  • For Q1 2026, EBT fell 28.17% year-over-year to -$25.5 million; the TTM value through Mar 2026 reached -$142.4 million, down 222.22%, while the annual FY2025 figure was -$139.5 million, 80.84% down from the prior year.
  • EBT hit -$25.5 million in Q1 2026 for Cartesian Therapeutics, up from -$77.4 million in the prior quarter.
  • Across five years, EBT topped out at $15.0 million in Q2 2024 and bottomed at -$196.7 million in Q4 2023.
  • Average EBT over 5 years is -$24.7 million, with a median of -$17.9 million recorded in 2023.
  • Year-over-year, EBT soared 5505.67% in 2022 and then tumbled 3608.62% in 2023.
  • Cartesian Therapeutics' EBT stood at $5.6 million in 2022, then crashed by 3608.62% to -$196.7 million in 2023, then soared by 87.66% to -$24.3 million in 2024, then plummeted by 218.7% to -$77.4 million in 2025, then surged by 67.08% to -$25.5 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$25.5 million, -$77.4 million, and -$19.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.